EGFR testing | GenomeWeb

EGFR testing

Quest Diagnostics will offer the Target Selector lung cancer mutation detection test in that country through a reference agreement with Biocept.

Non-small cell lung cancer patients with EGFR mutations now have three treatment choices, and AstraZeneca is working on newer personalized treatment options.

The raise is an extension of a $27 million Series B round in early 2014 to prepare for the launch of several liquid biopsy cancer tests this year. 

Data presented at the meeting helped better define the potential benefits and risks of broad panel-based tests for hereditary cancer genes.

The results also suggest the cfDNA assay has high sensitivity and 100 percent specificity, comparable to other technologies being developed for liquid biopsy testing.

Clovis hopes Sysmex's BEAMing test will work better than FFPE tests to identify candidates for treatment with rociletinib, its investigational EGFR inhibitor.

NEW YORK (GenomeWeb) — Researchers from several European institutions working with AstraZeneca have published a study demonstrating that measuring EGFR mutations from circulating tumor DNA compares favorably to tissue-based EGFR mutation status.

Originally published May 7.

Boehringer Ingelheim has launched a campaign to educate healthcare providers about biomarker testing to personalize treatment for non-small cell lung cancer patients.

Using a pharmacogenetic strategy to home in on a molecularly defined non-small cell lung cancer patient population, researchers have shown in a clinical trial that the investigational EGFR inhibitor afatinib significantly prolongs survival in patients with EGFR-mutated tumors.

Pages

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.